Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience Abstract #1764

Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.
Aim(s): To analyze the clinicopathological and molecular features of patients receiving TKI treatment, thus assessing toxicity and efficacy in our practice.
Materials and methods: Observational study. Period: January 2008 - May 2016. Statistical analysis: IBM SPSS Statistics 22.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Keywords: TNE, TKI

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Prof Rachel Riechelmann
#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Soledad Cameselle-Garcia
#3025 Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis
Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Alberto Bongiovanni
#3051 Epidemiology, Pathological and Clinical Features of 4307 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of the Spanish Neuroendocrine Cancer Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero
#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero